3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Breast Neoplasms
4
Stomach Neoplasms
1
Squamous Intraepithelial Lesions
1
Smoldering Multiple Myeloma
1
Psychological Well-Being
1
Ovarian Neoplasms
1
Muscle Invasive Bladder Cancer (MIBC)
1
Multiple Myeloma
1
Motor Activity
1
Monoclonal Gammopathy of Undetermined Significance
1
Malnutrition
1
Lung Neoplasms
1
Limited Stage Small Cell Lung Cancer
1
Inflammation
1
Helicobacter Infections
1
Esophageal Neoplasms
1
Diarrhea
1
Colorectal Neoplasms
1
Breast Carcinoma In Situ
1
Interventions
pembrolizumab
27
Oxaliplatin
24
Paclitaxel
22
Fluorouracil
21
Carboplatin
18
Leucovorin
16
Cisplatin
16
Capecitabine
16
Radiotherapy
15
Nivolumab
12
Drug Therapy
12
Radiation
10
Trastuzumab
9
Surgical Procedures, Operative
9
Immunotherapy
8
Magnetic Resonance Spectroscopy
7
Esophagectomy
7
Blood Specimen Collection
7
Taxes
6
durvalumab
5
Surveys and Questionnaires
5
Specimen Handling
5
Radiotherapy, Intensity-Modulated
5
Irinotecan
5
Immune Checkpoint Inhibitors
5
Docetaxel
5
Bevacizumab
5
tislelizumab
4
Ramucirumab
4
Fluorodeoxyglucose F18
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
Probiotics
×
1 year
×
Clear all
NCT04871412
2026-01-30
POISE
Ottawa Hospital Research Institute
Phase 3
Recruiting
20 enrolled